About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
My Favorite Dogs
Monthly Archives: December 2009
What is success in social media? Who in the medical product industry is making the best use of social media? For a nice qualitative overview – see "Are Pharmaceutical Companies on Twitter Satisfying Patients' Needs?" In my mind, the best … Continue reading
Everyone who works in crisis communications, or who may experience a crisis, should read this posting. The science of crisis communications got both faster, and more challenging with the advent of Twitter and the blogosphere. Citizen journalists can write a … Continue reading
Another late Weekly Roundup. My apologies. I have been on the road (Chicago this week) and fighting and losing a battle with a flu that is dragging on, and on, and on. Snow blanketed much of the nation this week. … Continue reading
It has been a busy week for Senator Charles E. Grassley (R-Iowa). In one of seven press releases he sent out about his activities on December 8, it was announced that the Senator was asking for information from thirty-three medical … Continue reading
While the FDA struggles to figure out how the Internet works , the Federal Trade Commission (FTC) forges onward. With the advent of the Internet, the FDA said – well, nothing. But another agency, the FTC, has been quite active … Continue reading